Signals from the BCR are generally considered the main drivers of CLL cell proliferation in vivo (1, 48) but it seems unlikely that constraints on BCR-signaling are being released by ruxolitinib as cytokines like IL-4 promote rather than inhibit this pathway in CLL cells (Figure 4) (8). This evidence concerns the gene IL4 and B-cell chronic lymphocytic leukemia.